Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704

The Pharmacogenomics Journal volume 12, pages 395–403 (2012)Cite this article

Subjects

Abstract

The aim of this study is to validate the prognostic and predictive value of the non-synonymous cytidine deaminase (CDA) Lys27Gln polymorphism for hematological toxicity and survival using a randomized phase III adjuvant trial (Radiation Therapy Oncology Group (RTOG) 9704) in pancreatic cancer in which one treatment arm received gemcitabine. CDA is involved in gemcitabine inactivation, and there is conflicting data on the role of the non-synonymous CDA Lys27Gln polymorphism in predicting toxicity and survival in cancer patients treated with gemcitabine. RTOG 9704 randomized 538 patients after pancreatic resection to receive radiotherapy with either 5-fluorouracil (5-FU) or gemcitabine. CDA Lys27Gln polymorphism genotype was analyzed. We tested an association between CDA single-nucleotide polymorphism genotype and the survival outcome by the Cox proportional hazard model adjusting for other covariates, as well as toxicity by the logistic regression model. There is statistically significant more severe hematological toxicity in patients treated with gemcitabine with either the homozygote wild-type genotype (Lys/Lys) alone (odds ratio (OR)=0.06, P=0.01), or in combination with the heterozygote (Lys/Gln; OR=0.14, P=0.03) when compared with homozygote variant genotype (Gln/Gln) when adjusted for other covariates. This was not seen in the non-gemcitabine treated arm. There are no genotype differences with respect to survival outcome. In conclusion, in this prospective randomized adjuvant study of patients with pancreatic cancer, the CDA Lys27Gln polymorphism is validated as a predictive marker of gemcitabine hematological toxicity, but not with treatment response or survival.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Burris III HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403–2413.

    Article  CAS  PubMed  Google Scholar 

  2. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58: 4349–4357.

    CAS  PubMed  Google Scholar 

  3. Tibaldi C, Giovannetti E, Vasile E, Mey V, Laan AC, Nannizzi S et al. Correlation of CDA, ERCC1, and XPD polymorphisms with response and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res 2008; 14: 1797–1803.

    Article  CAS  PubMed  Google Scholar 

  4. Tanaka M, Javle M, Dong X, Eng C, Abbruzzese JL, Li D . Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 2010; 116: 5325–5335.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Monzo M, Brunet S, Urbano-Ispizua A, Navarro A, Perea G, Esteve J et al. Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia. Blood 2006; 107: 4871–4879.

    Article  CAS  PubMed  Google Scholar 

  6. Okazaki T, Javle M, Tanaka M, Abbruzzese JL, Li D . Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res 2010; 16: 320–329.

    Article  CAS  PubMed  Google Scholar 

  7. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299: 1019–1026.

    Article  CAS  PubMed  Google Scholar 

  8. Regine WF, Abrams RA . Adjuvant therapy for pancreatic cancer: current status, future directions. Semin Oncol 2006; 33 (6 Suppl 11): S10–S13.

    Article  CAS  PubMed  Google Scholar 

  9. Garcia-Closas M, Malats N, Real FX, Yeager M, Welch R, Silverman D et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet 2007; 3: e29.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Steemers FJ, Gunderson KL . Illumina, Inc.. Pharmacogenomics 2005; 6: 777–782.

    Article  PubMed  Google Scholar 

  11. Fisher RA . On the interpretation of χ2 from contingency tables, and the calculation of P. J R Stat Soci 1922; 85: 87–94.

    Article  Google Scholar 

  12. Cox D . Regression models and life-tables. J R Stat Soc 1972; 34: 187–202.

    Google Scholar 

  13. Agresti A . Categorical Data Analysis. John Wiley and Sons: New York, 2002.

    Book  Google Scholar 

  14. Fukunaga AK, Marsh S, Murry DJ, Hurley TD, McLeod HL . Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway. Pharmacogenomics J 2004; 4: 307–314.

    Article  CAS  PubMed  Google Scholar 

  15. van Haperen VW, Veerman G, Vermorken JB, Pinedo HM, Peters G . Regulation of phosphorylation of deoxycytidine and 2′,2′-difluorodeoxycytidine (gemcitabine); effects of cytidine 5′-triphosphate and uridine 5′-triphosphate in relation to chemosensitivity for 2′,2′-difluorodeoxycytidine. Biochem Pharmacol 1996; 51: 911–918.

    Article  CAS  PubMed  Google Scholar 

  16. Eliopoulos N, Cournoyer D, Momparler RL . Drug resistance to 5-aza-2′- deoxycytidine, 2′,2′-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol 1998; 42: 373–378.

    Article  CAS  PubMed  Google Scholar 

  17. Bengala C, Guarneri V, Giovannetti E, Lencioni M, Fontana E, Mey V et al. Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma. Br J Cancer 2005; 93: 35–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Ganti AKP, Nguyen DA, Grem JL . Gene expression profile of enzymes involved in gemcitabine (Gem) metabolism in bone marrow mononuclear cells as predictors of myelosuppression. J Clin Oncol 2006 ASCO Annu Meet Proc Part I 2006; 24 (No. 18S (June 20 Suppl)): 2007.

    Google Scholar 

  19. Gilbert JA, Salavaggione OE, Ji Y, Pelleymounter LL, Eckloff BW, Wieben ED et al. Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics. Clin Cancer Res 2006; 12: 1794–1803.

    Article  CAS  PubMed  Google Scholar 

  20. Kirch HC, Schroder J, Hoppe H, Esche H, Seeber S, Schutte J . Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro. Exp Hematol 1998; 26: 421–425.

    CAS  PubMed  Google Scholar 

  21. Yue L, Saikawa Y, Ota K, Tanaka M, Nishimura R, Uehara T et al. A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity. Pharmacogenetics 2003; 13: 29–38.

    Article  CAS  PubMed  Google Scholar 

  22. Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N et al. Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 2005; 11: 2620–2624.

    Article  CAS  PubMed  Google Scholar 

  23. Ueno HO, Saijo NT . Association of genetic polymorphisms with survival in Japanese patients treated with gemctiabine (abstract). Eur J Cancer Suppl 2007; 5: 92.

    Article  Google Scholar 

  24. Sugiyama E, Kaniwa N, Kim SR, Kikura-Hanajiri R, Hasegawa R, Maekawa K et al. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism. J Clin Oncol 2007; 25: 32–42.

    Article  CAS  PubMed  Google Scholar 

  25. Mercier C, Evrard A, Ciccolini J . Genotype-based methods for anticipating gemcitabine-related severe toxicities may lead to false-negative results. J Clin Oncol 2007; 25: 4855; author reply 4855–6.

    Article  PubMed  Google Scholar 

  26. Mercier C, Raynal C, Dahan L, Ortiz A, Evrard A, Dupuis C et al. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 2007; 17: 841–844.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

JJF and JW were funded by RTOG Seed Grant, NIH K12 Career Development Award in Clinical Pharmacology. HE was funded by the American Society of Therapeutic Radiology and Oncology Junior Faculty Award.

Author information

Authors and Affiliations

  1. Division of Digestive Diseases, UCLA School of Medicine, Los Angeles, CA, USA

    J J Farrell & J Wong

  2. Department of Statistics, Radiation Therapy Oncology Group, Philadelphia, PA, USA

    K Bae

  3. Department of Radiation Oncology, Albert Einstein School of Medicine, Bronx, NY, USA

    C Guha

  4. Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA

    A P Dicker

  5. Department of Radiation Oncology, The Australian National University, Canberra, Australian Capital Territory, Australia

    H Elsaleh

Authors
  1. J J Farrell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Bae
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Guha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A P Dicker
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. H Elsaleh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J J Farrell.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Farrell, J., Bae, K., Wong, J. et al. Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704. Pharmacogenomics J 12, 395–403 (2012). https://doi.org/10.1038/tpj.2011.22

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2011.22

Keywords

This article is cited by

Search

Advanced search

Quick links